Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro-environment. Genenta’s lead product candidate, Temferon, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. For more information, visit the company's website at:

Nasdaq: GNTA
IR Website:
Headquarters: Milan, Italy and New York, NY

Content provided by Genenta Science on 2-24-22.


The Genenta Science Pharma management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.


Investor Presentation

Management Overview

Risks & Disclosures